CMB International: Raise the target price of Collumbotai Biotech (06990) to HK$645.62 to maintain the “buy” rating

Zhitongcaijing · 3d ago

The Zhitong Finance App learned that CMB International released a research report stating that it will raise the target price of Collumbotai Biotech (06990) by 0.5% from HK$642.99 to HK$645.62, maintaining the “buy” rating.

The bank said it will raise the DCF-based target price from HK$642.29 to HK$645.62 considering the smooth progress of SAC-TMT development. Short-term catalysts include ASCENT-GYN readings around the end of 2026, SAC-TMT approval progress in EC, further Trofuse Phase III data in 2027, and the launch of MK-2010 Joint SAC-TMT Phase III research in the first half of 2027.